Literature DB >> 8635189

Suppression of in vivo tumor growth by the transfection of the interleukin-5 gene into colon tumor cells.

Y Masuda1, S Mita, K Sakamoto, T Ishiko, M Ogawa.   

Abstract

To investigate the influence of tumor producing interleukin-5 (IL-5) on growth kinetics of tumors, we transduced the murine IL-5 gene into murine colon C26 tumor cells. Two IL-5-secreting clones, low-level IL-5 producer C26-8B and high-level IL-5 producer C26-6F, were established. Both tumors, C26-6F and C26-8B, grew more slowly than the mock C26 tumor, although the in vitro growth rate of these IL-5 transfectants was much the same as that of the mock C26 cells. There was a significantly decreased number of colonies in the lung of mice given C26-6F or C26-8B tumors i.v. than in mice given mock C26 tumors i.v. Moreover, in mice given C26-6F cells i.v., a smaller number of tumor colonies in the lung was observed, as compared to the case with C26-6B cells. While the growth rate of C26-8B tumors in mice treated with anti-IL-5 mAb was more rapid than that seen in control mAb-treated mice, growth of C26-6F tumors in anti-IL-5-mAb-treated mice was slightly more rapid compared to findings in control mAb-treated mice. The isotype-matched mAb did not alter the in vitro growth of mock-C26 cells or of the IL-5-gene-modified C26 cells. Growth of IL-5-secreting C26 tumors transplanted in nude mice was also inhibited. These results suggest that tumor-producing IL-5 inhibits growth of colon tumors mediated through T-cell-independent protective mechanisms of the host.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8635189     DOI: 10.1007/bf01526551

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  20 in total

1.  Retroviral interleukin 5 gene transfer into interleukin 5-dependent growing cell lines results in autocrine growth and tumorigenicity.

Authors:  T Blankenstein; W Q Li; K Uberla; Z H Qin; A Tominaga; K Takatsu; N Yamaguchi; T Diamantstein
Journal:  Eur J Immunol       Date:  1990-12       Impact factor: 5.532

2.  Production of a monoclonal antibody useful in the molecular characterization of murine T-cell-replacing factor/B-cell growth factor II.

Authors:  N Harada; T Takahashi; M Matsumoto; T Kinashi; J Ohara; Y Kikuchi; N Koyama; E Severinson; Y Yaoita; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

3.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

4.  An eosinophil-dependent mechanism for the antitumor effect of interleukin-4.

Authors:  R I Tepper; R L Coffman; P Leder
Journal:  Science       Date:  1992-07-24       Impact factor: 47.728

5.  Fibrosarcoma cells transduced with the IL-6 gene exhibited reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential.

Authors:  C A Mullen; M M Coale; A T Levy; W G Stetler-Stevenson; L A Liotta; S Brandt; R M Blaese
Journal:  Cancer Res       Date:  1992-11-01       Impact factor: 12.701

6.  In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5.

Authors:  L Rivoltini; V Viggiano; S Spinazzè; A Santoro; M P Colombo; K Takatsu; G Parmiani
Journal:  Int J Cancer       Date:  1993-04-22       Impact factor: 7.396

7.  Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors.

Authors:  H Karasuyama; F Melchers
Journal:  Eur J Immunol       Date:  1988-01       Impact factor: 5.532

8.  Establishment of mouse colonic carcinoma cell lines with different metastatic properties.

Authors:  M G Brattain; J Strobel-Stevens; D Fine; M Webb; A M Sarrif
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

9.  DNA rearrangement and constitutive expression of the interleukin 6 gene in a mouse plasmacytoma.

Authors:  T Blankenstein; Z H Qin; W Q Li; T Diamantstein
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

10.  Interleukin 5 enhances interleukin 2-mediated lymphokine-activated killer activity.

Authors:  T Aoki; H Kikuchi; S Miyatake; Y Oda; K Iwasaki; T Yamasaki; T Kinashi; T Honjo
Journal:  J Exp Med       Date:  1989-08-01       Impact factor: 14.307

View more
  1 in total

1.  Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo.

Authors:  T Nishimura; K Iwakabe; M Sekimoto; Y Ohmi; T Yahata; M Nakui; T Sato; S Habu; H Tashiro; M Sato; A Ohta
Journal:  J Exp Med       Date:  1999-09-06       Impact factor: 14.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.